Arbutus Biopharma Corp Preferred Stock, Including Additional Paid in Capital, Net of Discount
Arbutus Biopharma Corp (ABUS) had Preferred Stock, Including Additional Paid in Capital, Net of Discount of $0 as of 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Notes › Equity › Stockholders' Equity Note › Class of Stock Disclosures › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount · last filed 2022-03-03
- 2021-12-31: Preferred Stock, Including Additional Paid in Capital, Net of Discount $0.00.
- 2021-09-30: Preferred Stock, Including Additional Paid in Capital, Net of Discount $160.97M.
- 2021-06-30: Preferred Stock, Including Additional Paid in Capital, Net of Discount $155.89M.
- 2021-03-31: Preferred Stock, Including Additional Paid in Capital, Net of Discount $152.62M.
| Period end | Preferred Stock, Including Additional Paid in Capital, Net of Discount |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-03 |
| 2021-09-30 | $160.97M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $155.89M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $152.62M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $149.41M 10-K · filed 2022-03-03 |
| 2020-09-30 | $146.28M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $143.26M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $140.26M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $137.28M 10-K · filed 2021-03-04 |
| 2019-09-30 | $134.41M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $131.61M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $128.85M 10-Q · filed 2019-05-06 |
| 2018-12-31 | $126.14M 10-K · filed 2020-03-05 |
| 2018-09-30 | $123.49M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $120.92M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $118.38M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $49.78M 10-K · filed 2019-03-07 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |